Application of a mixed type of optimization in the implementation of pharmaceutical development of a dosage form of eye drops based on oligohexamethyleneguanidine hydrosuccinate

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This study focused on the implementation of the stages of pharmaceutical development of a dosage form of eye drops based on the branched oligohexamethylene guanidine hydrosuccinate according to discrete and continuous optimization, followed by risk assessment and process validation. Experimental samples were developed, critical process and quality parameters were identified, technological characteristics were measured, parameters were normalized, a forecast was made, confirmatory experiments were conducted, the optimal composition was identified, risks in the production of eye drops were assessed, and partial validation was performed. During the implementation of the stages of pharmaceutical development of eye drops based on branched oligohexamethylene guanidine hydrosuccinate, three optimization cycles (discrete and continuous) were carried out, and the optimal ratio of active and auxiliary components was justified based on the results (branched oligohexamethylene guanidine hydrosuccinate 0.05%, polyvinyl alcohol 1%, phosphate-buffered saline 20%, sodium chloride 0.45%, and purified water up to 100%). After reviewing the technological process considering risk analysis, critical points were identified, and partial validation was performed, and the positive results verified and confirmed the optimal choice at this stage of pharmaceutical development. In general, a mixed type of optimization (discrete and continuous) can be used to implement pharmaceutical developments of eye drops based on branched oligohexamethylene guanidine hydrosuccinate, which is confirmed by a series of experiments and risk assessment, and the partial validation verified the data obtained. Thus, pharmaceutical development is a complex and time-consuming process, and limited functionality does not always allow quick identification of the optimal composition of a drug. As an effective solution for implementing the stages of pharmaceutical development, mathematical modeling methods and various types of optimization can be applied.

Full Text

Restricted Access

About the authors

Denis O. Shatalov

Russian technological university

Author for correspondence.
Email: shat-05@mail.ru
ORCID iD: 0000-0003-4510-1721
SPIN-code: 3453-9987

MD, Сand. Sci. (Pharm.), associate professor

Russian Federation, Moscow

Diana A. Akhmedova

Russian technological university

Email: diana.akhmedova.123@mail.ru
ORCID iD: 0000-0002-0951-939X
SPIN-code: 4629-8311

assistant

Russian Federation, Moscow

Ivan S. Ivanov

Russian technological university

Email: ivan.ivanov1994@gmail.com
ORCID iD: 0000-0002-1346-7588
SPIN-code: 1899-6495

Сand. Sci. (Pharm.), researcher

Russian Federation, Moscow

Daria D. Kirillova

Russian technological university

Email: kirillova1541@mail.ru
ORCID iD: 0000-0002-3055-1116
SPIN-code: 8996-2103

master’s student

Russian Federation, Moscow

Yulia A. Koroleva

Russian technological university; Institute of Pharmaceutical Technologies

Email: jukka.hiden@bk.ru
ORCID iD: 0000-0001-8092-1990
SPIN-code: 5517-8014

master’s student

Russian Federation, Moscow; Moscow

Dmitry S. Minenkov

Ishlinsky Institute for Problems in Mechanics RAS

Email: minenkov.ds@gmail.com
ORCID iD: 0000-0001-6432-8134
SPIN-code: 6424-1334

MD, Сand. Sci. (Phyis.), Сand. Sci. (Math.)

Russian Federation, Moscow

Stanislav A. Kedik

Russian technological university

Email: kedik@mirea.ru
ORCID iD: 0000-0003-2610-8493

MD, Dr. Sci. (Tech.), professor

Russian Federation, Moscow

References

  1. Shilovskikh OV, Ponomarev VO, Kazaykin VN, et al. Bacterial keratitis. Part 1. Epidemiology, etiology, pathophysiology, risk factors, clinic, current aspects of diagnosis. Ophthalmology in Russia. 2023;20(1): 17–23. EDN: BSRWLW doi: 10.18008/1816-5095-2023-1-17-23
  2. Brzheskiy VV. Modern opportunities for the prevention and treatment of inflammatory eye diseases of an infectious nature in children. Ophthalmology reports. 2019;12(4):57–65. EDN: JQDGEV doi: 10.17816/OVI8917
  3. Azari AA, Arabi A. Conjunctivitis: a systematic review. J Ophthalmic Vis Res. 2020;15(3):372–395. doi: 10.18502/jovr.v15i3.7456
  4. Babushkin AE. Local antibiotic therapy of bacterial infectious and inflammatory diseases of the anterior segment of the eye (literature review). Point of view. East-West. 2021. № 2. С. 89–93. EDN: JFYMGR doi: 10.25276/2410-1257-2021-2-89-93
  5. Ivanov IS, Shatalov DO, Kedik SA, et al. Study of the effect of the pharmaceutical substance branched oligohexamethylene guanidine hydrosuccinate in relation to microorganisms. Antibiotics and Chemotherapy. 2019;64(11-12):8–15. EDN: RRPUIR doi: 10.1016/0235-2990-2019-64-11-12-8-15
  6. Kornyushko VF, Nikolaeva OM, Panov AV, et al. Quality management of the chemical-technological process for continuous synthesis of pharmaceutical substances of medicinal compounds in flow microreactors. Fine Chemical Technologies. 2021;16(3):252–266. EDN: GRYFHU doi: 10.32362/2410-6593-2021-16-3-252-266
  7. Ivanov IS. Microfluidic synthesis of hydrosuccinate-oligohexamethyleneguanidine substance and creation of ophthalmic preparation on its basis [dissertation]. Moscow; 2021. 118 p. (In Russ.).
  8. Shatalov DO. Development and standardization of quality control methods for branched oligohexamethyleneguanidine hydrochloride [dissertation]. Moscow; 2015. 137 p. (In Russ.).
  9. McDermott RE, Mikulak RJ, Beauregard MR. The basics of FMEA. 2nd edit. New York: Productivity Press; 2009, 90 р.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Traditional risk management process

Download (267KB)
3. Fig. 2. Algorithmic sequence of optimization cycles for the pharmaceutical development of eye drops

Download (1MB)
4. Fig. 3. Viscosity–rate curves of the experimental samples

Download (240KB)
5. Fig. 4. Release of the oligohexamethylene guanidine hydrosuccinate substance from samples of the eye drop dosage form

Download (294KB)
6. Fig. 5. Diagram of the manufacturing process of eye drops

Download (152KB)
7. Fig. 6. Ishikawa diagram for the risk assessment of eye drops

Download (1MB)
8. Fig. 7. Technological scheme of the processes for obtaining eye drops: НХ — NaСl; Кт — technological control; Кх — chemical control; Кмб — microbiological control

Download (486KB)

Copyright (c) 2024 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 77762 от 10.02.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies